Eli Lilly Acquires Kelonia for $3.25 Billion to Strengthen Cancer and Autoimmune Treatment R&D

Eli Lilly’s recent $3.25 billion acquisition of Kelonia Therapeutics marks a significant investment in innovative biotech, particularly in cell therapies for cancer. The deal signals Lilly’s strategic focus on expanding its expertise in CAR-T and autoimmune treatments amidst intense industry competition. Investors and industry analysts will watch whether this move accelerates Lilly’s development of promising therapies and impacts its market valuation.